{"name":"FibroGen","slug":"fibrogen","ticker":"FGEN","exchange":"NASDAQ","domain":"fibrogen.com","description":"Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.","hq":"San Francisco, CA","founded":0,"employees":"","ceo":"Thane Brooker (Interim)","sector":"Anemia / Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$180M","metrics":{"revenue":210000000,"revenueGrowth":-78.3,"grossMargin":0,"rdSpend":23517000,"netIncome":183452000,"cash":119594000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"roxadustat patent cliff ($1.4B at risk)","drug":"roxadustat","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"FibroGen reported fourth quarter and full year 2023 financial results, with net product revenue of $134.4 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"FibroGen Announces Collaboration with AstraZeneca to Develop and Commercialize Roxadustat in China","summary":"FibroGen entered into a collaboration agreement with AstraZeneca to develop and commercialize roxadustat in China.","drugName":"","sentiment":"positive"},{"date":"2023-09-11","type":"regulatory","headline":"FibroGen Receives Complete Response Letter from FDA for Roxadustat in Non-Dialysis-Dependent Chronic Kidney Disease","summary":"FibroGen received a Complete Response Letter from the FDA for roxadustat in non-dialysis-dependent chronic kidney disease.","drugName":"","sentiment":"negative"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9pUl9mX3hGVXk3MXRISDZzVnpVbTZJTWlHdnhvUjRGQ3I2NzhJZUY4UzdqbXFuUU5DU3dKd1NvSnFvWHc4RFY1MDRucmhUREQxLXN1dkdObzBZMFlhUjdZR0U1TVBsSThoMmdzaU5R?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Fibrogen Inc (FGEN) - Stock Titan","headline":"If You Invested $1,000 in Fibrogen Inc (FGEN)","sentiment":"neutral"},{"date":"2026-03-16","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-16","type":"pipeline","source":"simplywall.st","summary":"Is FibroGen (NASDAQ:FGEN) A Risky Investment? - simplywall.st","headline":"Is FibroGen (NASDAQ:FGEN) A Risky Investment?","sentiment":"neutral"},{"date":"2025-11-10","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPa1BNMjA0eVBYdmlZdmZPNkpiOXF3cjU5VEZHSVRnc1YzT1F0bHBFVTA3UnlxbUwyd1c3WGZ4cG00ck9fenhRcWh3QVhleVBHbXhnUXRlbGRXUmtmX2RlcER3THN4MW8wdWU4dTlia3ljYURONFQ1Nld4dWV2aUNraURQeXJYQlJiOTh5eUk2YkRPR29hUWlBT0tDR0NiRS1FRjlBR0dGX1NiUTRoQnNKazR0QzhxcjBsSnA1Rg?oc=5","date":"2025-09-12","type":"pipeline","source":"The Pharma Letter","summary":"$1.25 million penalty for FibroGen over ‘false and misleading statements’ case - The Pharma Letter","headline":"$1.25 million penalty for FibroGen over ‘false and misleading statements’ case","sentiment":"neutral"},{"date":"2025-09-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-09-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-08-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxPZ29RWlF6TVkzMVV4VjVYT1QzZGdoWnd6dUlyR2dlcmpOOEJKcDJDckI4R1phbnQzTjVZWmpQdF8tczF5QWRGMEpDNzVzOUhYUm9xaUlXaWxvVkR2SlRpdmNrUFRBVm5ZNGE4b3NOLW13ZU5pMW5IVVFldkk1T1Bjdl9aZHduMkY1MW9sVUFwenRnZjN4WEVZT3piR3hPenVzdmhtYWVJSTBPemtrRlRndF9NOEdFR1VJWkkxQ2xEQnlNVVdSVFFMT1pQNjhNOERoY1pDb0x6X1_SAd4BQVVfeXFMT2RCVGs4V3lYdGdzR3A0dE5mUEVSNFY3YnpFa1g2STBUV0FGdS1NcXhBOXZRWFNPZGFadm5pQXFDWFR1ZXlSS0NkRkg3OW42eUdpcDhvZEVGVDRPMGoyS0lQTEp5dWc0VVRFVGNhWkVnN0pVbmdYMlk0YzgtaXBNeV84M2doNkIwU2VKeHhfaGhlVmR6bTRmbmFUWVExNzc2MTY4TDhBNjRYblJTRWtFdGl6NU04NU00ZDRWNGF6TENmMDIzbjYzOHp5d0cyLVdkb1htOGtVbG9SMXE2OFdR?oc=5","date":"2025-04-08","type":"pipeline","source":"simplywall.st","summary":"Investors Don't See Light At End Of FibroGen, Inc.'s (NASDAQ:FGEN) Tunnel And Push Stock Down 26% - simplywall.st","headline":"Investors Don't See Light At End Of FibroGen, Inc.'s (NASDAQ:FGEN) Tunnel And Push Stock Down 26%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOQ3A2SE5HM3VLTFRIQlktT3hSb0d5czBMakxzWnNKaDBpM0dsRXhtSVZzSDR0b1Nvc0pSYlNqWFBrR1FTUnJPenFHckZ5OWhMdzlRX1VOdkpBbXVnT0ZidnBpWnluMFBPZU1GZ29PTTNGUFRuUmFsS3BKNllYLXYwZERsbjVaLXcyMGRnQ3kzLS1QSWdfc3pyLS1NSW11NU5fOUJ6dlpwZ1YwSWxTUl9z?oc=5","date":"2025-02-20","type":"deal","source":"Reuters","summary":"AstraZeneca boosts China presence with FibroGen's anemia drug in $160 million deal - Reuters","headline":"AstraZeneca boosts China presence with FibroGen's anemia drug in $160 million deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQZjgxRXJXYkdYZ09pNm1BRTFENEZrRUNPbUp0Ti1MdTJuTkJzOGdqVTZkbGlzRDNkNmJybkhFM3NFZHhrRWRES1gyTjNBaEV4aFF2UXBrZm1oYzhpNk5RUkhuR3BpNVBfR2l4cVFBNE9VcGJaSXpIWFc5UFJURU9WenVn?oc=5","date":"2025-02-20","type":"pipeline","source":"The Pharma Letter","summary":"FibroGen sells China business to AstraZeneca - The Pharma Letter","headline":"FibroGen sells China business to AstraZeneca","sentiment":"neutral"}],"patents":[{"drugName":"roxadustat","drugSlug":"roxadustat","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":1400000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Amgen","Bayer","Merck & Co."],"therapeuticFocus":["Anemia","Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":6440000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":6440000,"period":"2025-12-31"},{"value":29621000,"period":"2024-12-31"},{"value":29621000,"period":"2024-12-31"},{"value":147752000,"period":"2023-12-31"},{"value":46803000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":23517000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":183452000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":119594000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}